Last reviewed · How we verify
Oxybutynin Chloride Extended-Release Tablets, 15 mg
At a glance
| Generic name | Oxybutynin Chloride Extended-Release Tablets, 15 mg |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg (PHASE1)
- Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (PHASE4)
- Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition (PHASE4)
- Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: